Gastrointestinal Side Effects in Postmenopausal Women Using Osteoporosis Therapy: One-Year Findings in the POSSIBLE U.S. Study

• Activity Number: 257
• Type: Contributed
• Date/Time: Monday, August 2, 2010 : 2:00 PM to 3:50 PM
• Sponsor: Section on Statistics in Epidemiology
• Author(s): Guozhi Gao*+ and Claudine Woo and Sally Wade and Marc Hochberg
• Companies: Amgen Inc. and Amgen Inc. and Wade Outcomes Research and Consulting and University of Maryland
• Keywords: postmenopausal ; gastrointestinal side effect ; health-related quality of life ; bisphosphonate

Abstract

The objective of this research is to characterize gastrointestinal side effects (GI SEs) and its associations with medication discontinuation, health-related quality of life (HRQoL) and treatment satisfaction in postmenopausal women prescribed osteoporosis (OP) therapies. POSSIBLE US participants enrolled October 2004-January 2007 and complete questionnaires for up to 3 years. GI SEs for women new to or stable on therapy at entry were characterized at 6 and 12 months. Adjusted odds of experiencing GI SEs; mean HRQoL and treatment satisfaction scores; and risk of discontinuing therapy for bisphosphonate (BP) versus non-BP users were compared with logistic and generalized linear models. About 20% of women reported =1 GI SE at entry. GI SEs at month 6 were more common in BP than non-BP users. Women new to OP therapy with GI SEs at month 6 had lower LS Mean HRQoL and treatment satisfaction.